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We present a platform that combines microarrays and microfluidic techniques to measure four protein
biomarkers in 1024 serum samples for a total of 4096 assays per device. Detection is based on a surface
fluorescence sandwich immunoassay with a limit of detection of ~1 pM for most of the proteins
measured: PSA, TNF-α, IL-1β, and IL-6. To validate the utility of our platform, we measured these four
biomarkers in 20 clinical human serum samples, 10 from prostate cancer patients and 10 female and
male controls. We compared the results of our platform to a conventional ELISA and found a good
correlation between them. However, compared to a classical ELISA, our device reduces the total cost of
reagents by 4 orders of magnitude while increasing throughput by 2 orders of magnitude. Overall, we
demonstrate an integrated approach to perform low-cost and rapid quantification of protein biomarkers
from over one thousand serum samples. This new high-throughput technology will have a significant
impact on disease diagnosis and management.Introduction
The primary applications of microfluidics in the health-care
sector have been in the form of point-of-care (POC) medical
diagnostic devices,1 aimed at measuring one or a few analytes
from a single sample, with reasonably fast turn-around times.
While significant progress has been demonstrated it is still dif-
ficult to assess whether these technologies and their commer-
cialization would outweigh the many advantages provided by
centralized laboratories such as quality, cost reduction, assay
sensitivity, specificity, reproducibility, regulations, and perfor-
mance.2 Disappointingly, little progress has been made in
developing microfluidic devices capable of outperforming auto-
mated clinical sample analyzers in terms of throughput and
cost reduction. Automated clinical sample analyzers are large,
expensive robotic workstations capable of performing hundreds
of tests per hour and are commonly found in centralized labora-
tories or hospitals. For example, the Cobas 8000 (e 602 module)
from Roche and the Architect i4000SR from Abbot, amongst
others, can perform up to 170 and 400 immunoassays per
hour, respectively. This translates to 1530–3600 assays for a
9 h workday and 4080–9600 assays in 24 hours.
The importance of high-throughput immunoassays will
continue to increase as more biomarkers are being identifiedand personalized medicine becomes prevalent. To monitor
disease progression or predict disease risk will require
analysis of a multitude of biomarkers including genomic,
proteomic, transcriptomic, metabolomic, and autoantibody
profiles.3 However, current clinical sample analyzers do nei-
ther meet the demand in throughput nor drastically reduce
the cost per assay, as the assay volumes are not significantly
reduced when compared to standard bench-top ELISA assays.
Thus, although a throughput of 9600 assays in 24 hours is
reasonably impressive, microfluidic technologies could not
only further enhance throughput, but also decrease the cost
per assay dramatically, making large panel biomarker screen-
ing affordable and realistic. Any low-cost immunoassay tech-
nology for the large-scale analysis of samples would have a
significant impact in clinical research, the diagnosis of dis-
eases, and the monitoring of an individual's health, because
tests could be performed more frequently without incurring
additional costs on the health care system.
One approach to decrease the cost of immunoassays is to
reduce the volume of reagents needed to run them (in partic-
ular the total volume of antibodies), which in turn requires
reducing the sample volume. Reducing the amount of sample
also has other implications because more analytes could be
measured from the same sample, even for analytes for which
an antibody has not yet been developed. This is particularly
useful for samples stored in biobanks4 or accrued during
clinical studies. However, reducing sample volume alone is
not sufficient, as it has to be accompanied by an integrated
and automated approach to handle thousands of samples
simultaneously so that costs can be further decreased whileLab Chip
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View Article Onlineretaining the same assay quality and reproducibility. This
approach is difficult to implement on very small volume
scales using liquid handling robots.5 Microfluidics is a more
suitable alternative. While there have been a few attempts to
measure analytes from nanoliter volume samples, they are
limited in sample throughput and do not multiplex analytes.6
In this paper, we describe a microfluidic platform (Fig. 1),
which combines microarraying and microfluidic techniques,
to create an integrated microfluidic device capable of analyz-
ing 4 biomarkers in 1024 nanoliter-volume samples for a total
of 4096 assays per device. The platform increases the through-
put of a previous device which we applied to a cell culture
analysis by ~2.6 fold,7 and we show here that the approach
can be applied to quantitate biomarkers in clinical human
serum samples. Compared to our previous platform, we
redesigned the layout of the chip to fit 1024 assay units on
the area of a microscope glass slide (75 mm × 25 mm), includ-
ing the space required for 23 pressure control lines, 9 inlets,
and 2 outlets.
Although operating at extremely low sample volumes of
5 nL, we were able to achieve similar sensitivities as a con-
ventional ELISA, the current gold standard for protein bio-
marker quantitation. This unprecedented throughput, low
sample volume consumption, and straightforwardmicrofluidic
design allow several improvements over ELISA: (i) the total
volume and cost of reagents is decreased >40 000-fold, (ii) the
amount of antibody is reduced >10 000, and (iii) the time to
run an assay is reduced by ~20-fold.
Materials and methods
Device fabrication
Microfluidic devices were fabricated by multilayer soft-
lithography, as previously described.7 The control layer mold
consisted of ~30 μm structures patterned on negative photore-
sist (GM1070, Gersteltec, Switzerland) whereas the flow layer
mold was made with positive photoresist (AZ9260, Clariant
GmbH, Germany) coated to a height of ~10 μm. The flow layer
mold was baked at 180 °C in a convection oven for 1 hour toFig. 1 Workflow for massively parallel immunoassays of clinical samples
laboratories are automatically spotted with a microarray robot. Protein s
calibration standard. A microfluidic device is aligned to the array. Eight diff
the chip to control fluid movement. The chip is run the next day with m
clinician or researcher.
Lab Chipround the structures. Devices were cast in polydimethylsiloxane
(PDMS, Sylgard 184, Corning, USA). PDMS was poured into
the control mold to a thickness of 5 mm and was spin-
coated on the flow layer mold at 2100 rpm for 60 s. Both
molds were baked for 30 min at 80 °C. Chips from the con-
trol layer mold were cut, peeled from the mold, aligned to
the flow layer mold, and baked for an additional 90 min at
80 °C. Aligned devices were again cut and peeled from the
mold. Holes were punched using a precision manual-
punching machine (Syneo, USA).
Surface chemistry and reagents
Microscope glass slides were coated with epoxysilane to
covalently immobilize proteins to the surface of the glass.8
Briefly, glass slides are bathed for 30 min in a mixture of
720 mL milli-Q water and ammonia solution (5 : 1 ratio) and
150 mL of hydrogen peroxide. Next, glass slides were incu-
bated for 20 min in a solution of 1% 3-glycidoxypropyl-
trimethoxymethylsilane in toluene. The glass slides were
dried and baked for 30 min at 120 °C in a convection oven,
after which they were sonicated in toluene, rinsed with
isopropanol, and blow-dried. Glass-slides were stored at room
temperature in a vacuum-desiccator. Biotinylated bovine
serum albumin, BSA (29130), neutravidin (31000), and 1%
blocker casein in PBS (37528) were purchased from Thermo
Fisher Scientific. Neutravidin conjugated with different
fluorescent dyes (Dylight 488, 550, 650, Thermo Scientific)
enhanced green fluorescent protein (E-GFP, 4999-100, BioVision),
and biotinylated anti-GFP antibody (ab6658, Abcam) were
also acquired.
Antibodies and proteins
Anti-human PSA monoclonal antibodies matched pairs
(10-P20E and 10-P20D) and purified native human PSA pro-
tein (30C-CP1017U) were purchased from Fitzgerald Indus-
tries International (MA, USA). The rest of the anti-human
antibodies matched pairs and human protein standards were
bought from eBioscience: IL-6 biotin-conjugate (13-7068-81),. Samples collected from biobanks, clinical trials, hospitals, or clinical
tandards are also spotted on the same array to serve as an internal
erent reagents are needed to operate the chip. Tubing is connected to
inimum operator intervention. Data are analyzed and reported to the
This journal is © The Royal Society of Chemistry 2014
Lab on a Chip Paper
Pu
bl
ish
ed
 o
n 
26
 N
ov
em
be
r 2
01
3.
 D
ow
nl
oa
de
d 
on
 1
8/
12
/2
01
3 
10
:0
6:
41
. 
View Article OnlineIL-6 PE-conjugate (12-7069-81), IL-6 protein standard
(39-8069-65), IL-1β biotin-conjugate (13-7016-81), IL-1β
PE-conjugate (13-7016-81), IL-1β protein standard (39-8018-65),
TNF-α antibody functional grade purified (16-7348-85), TNF-α
PE-conjugate (12-7349-81), TNF-α protein standard (39-8329-65).
Anti-human PSA and TNF-α antibodies (10-P20E and 16-7348-85,
respectively) were biotinylated using the ChromaLink One-Shot
Antibody Biotinylation kit (Solulink). Finally, the 10-P20D PSA anti-
body was conjugated with phycoerythrin using the R-PE Antibody
All-in-One Conjugation kit (Solulink). ELISA diluent solution
(00-4202-56, eBioscience) was used to re-suspend protein standards
and dilute samples.ELISA
Human PSA-total ELISA kit (ELH-PSATOTAL-001) was pur-
chased from RayBiotech, Inc. The 96-well ELISA plate assay
was performed according to the manufacturer instructions.
Serum samples were diluted 2- and 10-fold; PSA protein stan-
dards were prepared using both the ELISA kit and the native
human PSA protein. 100 μL volume samples were pipetted
into the wells, incubated for 2.5 hours at room temperature,
washed extensively, and incubated with biotinylated anti-PSA
antibody for 1 hour, followed by another washing, incubation
for 45 min with streptavidin, washing, and incubation with
TMB substrate for 30 min. Finally, 50 μL of stop solution was
added to each well to stop the reaction. The absorbance of
each well was quantitated with a microplate reader (Synergy
Mx, Biotek Instruments).Human clinical specimens
Human serum samples were purchased from Asterand (UK).
Our samples consisted of 10 patients who were diagnosed for
prostate cancer and 10 control samples (5 female and 5 male).
Medical records of each patient are included in ESI,† Table S1.Spotting
Samples were spotted on the epoxy-coated glass slide using
the same spotting protocol previously described.7 Briefly,
samples were spotted from a 384-well microtiter plate onto
an epoxy-coated glass slide with a 4.9 nL delivery-volume
spotting pin (946MP8XB, Arrayit, USA) using a microarray
robot (QArray2, Genetix) at 60% humidity. The resulting
spots were ~350 μm in diameter. The microfluidic device was
aligned on top of the spotted glass slide and bonded over-
night in the dark at 40 °C.Control line priming
Control lines on the chip were primed with deionized water
at 4 psi. Upon observation that control lines were fully
primed, the pressure was increased to 23 psi. During the
experiments, all flow lines were operated at 3.2 psi.This journal is © The Royal Society of Chemistry 2014Optical read-out, quantification and statistics
The microfluidic device was scanned with an exposure time
of 1 s using a fluorescent microarray scanner (Arrayworx,
Applied Precision, USA) outfitted with a Cy3 filter (540/25 X,
595/50 M). The resulting TIFF-images were manually analyzed
using a microarray image analysis software (GenePix Pro v6.0,
Molecular Devices) and Matlab (Mathworks). Statistical and
nonlinear regression analysis was performed using Prism
v5.0 (Graphpad).
Results and discussion
Microfluidic design and operation
The microfluidic device consists of a flow and control layer
fabricated by multi-layer soft-lithography to facilitate control
and automation of the assays. The PDMS device is 68 mm
long, 20 mm wide, and ~4 mm thick (Fig. 2.a, ESI,† File S1),
and is bonded to a 25 mm × 75 mm glass slide. The device
contains 1024 assay units separated from each other with a
“sandwich” valve. Each assay unit comprises a spotting cham-
ber and an assay chamber (white dotted circles in Fig. 2.b).
The spotting chamber is aligned on top of the spotted sample.
A valve separates the spotting chamber from the assay cham-
ber. The assay chamber contains four deflectable button mem-
branes (MITOMI)7,9,10 that perform a total of 4096 assays per
chip. The device contains a total of 7198 valves, which are
operated using 14 pneumatic control lines. Reagents can be
loaded onto the chip through nine fluidic ports, which are con-
trolled by a multiplexer. Two outlets, one used for bubble purg-
ing and one for waste, are controlled with their respective valve.
MITOMI button-membranes facilitate immobilization of the
different antibodies as well as incubation and washing steps
without loss of bound material.9 Spotted samples are dried
before aligning and are kept in that state until the start of the
experiment (ESI,† Fig. S1). Baking the device overnight at 40 °C
is sufficient to bond the PDMS device to the epoxy glass slide.
This bond is strong enough to withstand the fluidic pressures
required during normal chip operations. After the control lines
are actuated, the hygroscopic sample spots begin to slowly
rehydrate due to water diffusion through the PDMS from the
neck valve on the control (top) layer to the flow (bottom) layer.
Two fluidic capacitors are located on top of the spotting cham-
ber (in front to the neck valve) to relieve some of the pressure.
Previous designs that did not include the capacitors resulted in
leakage of the spotted samples into the assay chamber during
the assay due to fast rehydration and high internal pressures.
The relief valve, which leads to an overflow channel, is opened
at the end of the incubation step to relieve built-up pressure
and allow closing of the neck valves.
At the beginning of the assay, the control lines are primed
at low pressures (4 psi) to avoid fast rehydration of the sam-
ples that could pervade into the assay chamber and lead to
contamination. After the lines are primed (~3 min), the pres-
sure is increased to 23 psi, and the neck valves and relief
valves are closed to isolate the chambers with the spotted
samples for the duration of the surface patterning steps.Lab Chip
Fig. 2 Chip design. (a) Dimensions of the microfluidic device. Blue and red colors denote control and flow layers, respectively. (b) The assay unit
can be divided into a spotting chamber and an assay chamber (highlighted by white dotted circles). MITOMI button membranes are located in the
assay chamber. See text for a detailed description. (c) Assay workflow showing a simplified schematic of a single assay unit with the spotted
sample (top row) and a cross-sectional view of the volume between one button membrane (PDMS) and the surface (bottom row). Biotinylated
BSA is immobilized on the surface directly underneath the buttons (i). Spotted sample begin to rehydrate. Neutravidin molecules are bound to
the biotin groups of the BSA (ii). Biotinylated capture antibodies are bound to neutravidin (iii). After incubation with the sample, (iv) the button
membranes are actuated (v) to protect the bound analytes during the wash step. A cocktail of fluorescent detection antibodies is incubated with
the antigen–antibody complex (vi). The button membrane is actuated again to protect the sandwich complex during the final washing step (vii).
The clock shows approximate duration of every step in hours. (d) Fluorescent scanning image of the full chip with different colored neutravidin
molecules immobilized under the button membranes. The image shows a total of 4096 assays. Alexa 488, Cy3, and Cy5 fluorescence channels
were colored blue, green, and red, respectively.
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View Article OnlineEvery single step described next is followed by a washing step
for 10 min with PBS/Tween 0.05%. First, biotinylated BSA
(2 mg mL−1) is flowed through the chip for 40 min followed
by neutravidin for 40 min (Fig. 2.c.i). Next, the four button
membranes are actuated and biotin–BSA flowed again for
40 min. A layer of neutravidin remains under the area
protected by the deflected button membranes (Fig. 2.c.ii).
The primary antibody immobilization step uses biotinylated
antibodies. Each antibody is flowed for 40 min at a concen-
tration of 2 μg mL−1 (diluted in casein) with the correspond-
ing button membrane open while the other 3 buttons remain
closed (Fig. 2.c.iii). At this point, all samples throughout the
chip have rehydrated. The sandwich valves are closed to pre-
vent cross-contamination between chambers and the neck
valve is opened to allow the sample to diffuse into the assay
chamber (Fig. 2.c.iv). We incubate the sample for two hours
(see next section) to ensure complete equilibration of the
sample and the four analytes.Lab ChipTo remove any unbound material in the assay chambers,
the MITOMI buttons are closed and the relief valves are
opened for a few seconds. Thus, the internal pressure which
continues to increase during the incubation step is released,
in turn allowing the button membranes to fully deflect and
trap the primary antibody–analyte complex (Fig. 2.c.v). Next,
the neck valves are closed and the sandwich valves are
opened. Washing for 30 min ensures removal of any
unbound material. A cocktail of four fluorescent detection
antibodies (each at a concentration of 400 ng mL−1) is flowed
through the chip for 20 min with the button membranes
closed. The flow is stopped, the sandwich valves are closed,
and the button membranes are opened for 20 minutes in
order to let the detection antibodies bind to the primary anti-
body–analyte complex (Fig. 2.c.vi). Closing the button mem-
branes protects the sandwich immunocomplex. Next, the
sandwich valves are opened, and the assay chambers
are washed for 30 min to remove any unbound materialThis journal is © The Royal Society of Chemistry 2014
Fig. 3 Protein standards. Fluorescent intensities of the dilution curves
for TNF-α, IL-6, IL-1β, and PSA measured with our chip. Error bars:
1 standard deviation (s.d.), n = 5.
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View Article Online(Fig. 2.c.vii). Fig. 2.d shows an example of a fluorescent
image of the chip with the area under the button membranes
patterned with different fluorescently labeled neutravidin
molecules.
Incubation time
We used GFP (MW = 32.7 KDa) to determine the optimal
time for the incubation step. GFP was spotted at concen-
trations ranging from 163 ng mL−1 to 327 pg mL−1 (5 nM to
10 pM), equivalent to a range of 3.9 × 106 to 7800 molecules.
A biotinylated anti-GFP antibody was immobilized on one of
the button membranes of the bottom row with the longest
diffusion distance. We acquired time-lapse fluorescence mea-
surements of the chip every 10 minutes for 150 min. ESI,†
Fig. S2.a shows the response curves for the different con-
centrations. While binding for analyte concentrations above
1 nM occurs in a matter of minutes, it takes about 1 hour
to capture ~90% of the molecules present at 10 pM. Thus,
incubation of at least one hour is needed to detect concen-
trations as low as 10 pM. After 150 min of incubation, the
button membrane was closed, and the assay chambers were
washed for 30 min, showing that even after a thorough
washing the button membranes are effective in trapping the
bound antibody–antigen complex, even at the lowest detected
concentration of 10 pM (ESI,† Fig. S2.b).
Calibration curves and ELISA comparison
We evaluated the performance of our chip by comparing our
chip based measurements of four different biomarkers to
values obtained with commercial ELISA kits. We found limits
of detection (LOD, intensity of lowest analyte concentration
that has a value higher than the mean of a negative control
plus two standard deviations) to be 62.5 pg mL−1 (3.67 pM)
for TNF-α, 15.6 pg mL−1 (742 fM) for IL-6, 15.6 pg mL−1
(897 fM) for IL-1β, and 31.25 pg mL−1 (1.04 pM) for PSA
(Fig. 3). The sensitivity of our technology is therefore ~1 pM,
or ~800 molecules per unit chamber. These LOD values
are similar to those reported in the literature employing
microfluidic devices;6,11–13 however, our device requires only
~5 nL of sample, which is at least 1000 times smaller than
what most microfluidic devices currently require.
Standard curves for the cytokines are comparable to
ELISAs that use the same antibody pairs (see for example
datasheets of ELISA kits for human TNF-α, IL-1β, IL-6:
BM223INST, BMS224INST, BMS213INST, respectively, from
eBioscience). Concentrations lower than 1 ng mL−1 for
these cytokines and PSA showed no cross-reactivity with the
other analytes.
Because the PSA standard used in the chip (native purified
protein) was different from the ELISA kit (recombinant
protein), we decided to compare both proteins as measured
by ELISA. We found that both proteins have the same LOD
of 125 pg mL−1 (4.16 pM) and similar standard curves
(ESI,† Fig. S3). Interestingly, the ELISA measured sensitivity
is ~15-fold higher than the sensitivity reported by theThis journal is © The Royal Society of Chemistry 2014manufacturer (8 pg mL−1 or 266.7 fM). In contrast, the LOD
measured on-chip was 31.25 pg ml−1 (1.04 pM), 5-fold higher
than the reported ELISA LOD.Clinical results
To evaluate the utility of our technology, we measured the
same 4 biomarkers in 20 human clinical samples using our
chip and compared them to a standard ELISA (performed in
our lab) and to values provided by the serum supplier. Ten of
the clinical samples were from male patients diagnosed with
prostate cancer, with total-PSA values measured at the time
of sample collection (Fig. 4.a, top row). The other ten clinical
samples were controls coming from five female and five male
donors younger than 40 years of age (Fig. 4.a, bottom row),
for which there were no total-PSA measurements available.
The serum samples were thawed and diluted 2- and 10-fold
in standard ELISA buffer. The original serum sample and the
dilutions, together with the four protein standard calibration
samples, were spotted on an epoxy-coated glass slide, aligned
to the chip, baked overnight, and run the next day. All samples
were assayed in quintuplicates, for a total of 475 spotted sam-
ples and 1900 assays per chip. Fluorescence intensity units
from the protein dilutions were analyzed with a 4-parametric
logistic regression. Picogram per milliter values were derived
from the curve fit.
Values measured on-chip and with ELISA are generally
lower than the ones reported by the serum supplier (Fig. 4.b),
possibly due to sample degradation or sub-optimal storage
conditions since the original measurement. Others have also
observed a slight decrease in total PSA values over time.14
Most of the samples used in this study were collected in 2011
and some as early as 2006. However, there is a goodLab Chip
Fig. 4 Performance comparison on patient sera. (a) Grouped bar
graph of total-PSA values measured with the chip, a conventional
ELISA, and values provided by the supplier. Top and bottom rows
correspond to data from 10 prostate cancer patients and 10 control
samples, respectively. x denotes no information provided by the
supplier. (b) The same data from the top row in (a) is shown in the form
of a scatter plot. (c) Correlation between ELISA performed in our lab
and the chip. Error bars: 1 s.d. (n = 5, chip and n = 2, ELISA).
Fig. 5 Multiplexed biomarker measurements from human blood sera.
Bar plot measurements of PSA, IL-6, and IL-1β for the 20 serum sam-
ples employing the chip. TNF-α was not detected in the samples. Data
are arranged into three groups: female and male controls and prostate
cancer patients. Error bars: 1 s.d., n = 5.
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View Article Onlinecorrelation (R2 = 0.79) between the values obtained with the
chip and the ELISA performed in our lab (Fig. 4.c). Even for
samples that were diluted 2- or 10-fold, our chip shows the
same sensitivity as a conventional ELISA (ESI,† Fig. S4).
Measurements for the other biomarkers are shown in ESI,†
Fig. S5. The average coefficient of variation (CV) for the chip
and ELISA is 23.45% and 29.79%, respectively. These results
validate the utility of our technology to assay clinical human
serum samples in high throughput.
Measurements for the other biomarkers are shown in
Fig. 5. The current cut-off value of total-PSA used for diagnos-
ing prostate cancer is 3–4 ng mL−1,15 which is ~100 times
higher than the LOD of our chip (31.25 pg mL−1). Interestingly,
some of the female control samples showed elevated values of
PSA, >100 pg mL−1. PSA has emerged as a potential biomarker
for diagnosing breast cancer,16 with a median of 1.3 ng mL−1
total-PSA for breast cancer patients17 and of 670 pg mL−1 for
women with breast cysts.18 The sensitivity of our chip is thus
well suited to detect both types of conditions. Levels of IL-6
were also generally higher for prostate cancer patients than for
the controls. IL-6 level has been shown to correlate with the
extent of disease in prostate cancer patients.19 Female sample
controls showed a correlation of IL-1β and PSA levels. IL-1β
levels were in general higher for prostate cancer patients with a
Gleason score ≥7, in agreement with recent findings.20 TNF-α
was not detected in any of the samples.
Benchmark of ELISA vs. serum analyzer chip
We quantify the advantages of our serum analyzer chip by
comparing the reagent volume consumption, time, and total
cost of running a chip against a typical ELISA, the current
gold standard for protein quantitation (Table 1, ESI,† Table S1).Lab ChipThe reduction in sample volume is considerable with a
10 000-fold reduction, while achieving similar limits of detec-
tion as with current state-of-the-art microfluidic based
approaches. This sample volume reduction, together with
the design of our chip, also decrease the amount of capture
and detection antibody required by over 4-orders of magni-
tude. Antibodies are the most expensive components in an
immunoassay, and as recently reported by Wu et al.21 there
can be quality variations between batches of the same anti-
body. With 50 μg of antibody we can run almost 10 000 chips
or ~10 000 000 assays.
Interestingly, over 80% of the total cost to run a chip cur-
rently stems from the surface passivation reagents (Biotin–
BSA and Neutravidin, ESI,† Table S1), which suggests that
further decrease in cost could be possible by other more afford-
able and simple surface passivation methods.22–24 One key
advantage of our chip is that it does not require an enzymatic
amplification step to achieve high sensitivity, but rather uses
fluorescently labeled detection antibodies (phycoerythrin),
which helps reduce the cost and complexity of the assay.
Conclusions
We have demonstrated an integrated microfluidic platform
capable of measuring 4 biomarkers in 1024 blood serumThis journal is © The Royal Society of Chemistry 2014
Table 1 Comparison of reagent consumption, time, and cost using our chip and a 96-well plate conventional ELISA, per biomarker
This platform (per assay unit) ELISA (per well) Fold improvement
Sample volume 5 nL 50 μL 10 000
Capture antibody amount ~5 pg >50 ng >10 000
Detection antibody amount ~100 fg >5 ng >50 000
Standard protein volume 5 nL 100 μL 20 000
Enzymatic amplification step No Yes
Multiplexing 4 1 4
LOD (PSA, this work) 31.25 pg mL−1 125 pg mL−1 (8 pg mL−1)a Same
Time to run a single assayb 13 s 243 s 18
Automation Microfluidics None —
Effective area per assay 0.48 mm2 31.67 mm2 66
Reagent consumption volumec 29 nL per assay unit 1550 μL per well ~53 500
Cost of reagents per assay ~US$0.0001 $3.82 >40 000
Total cost of reagents to run a chip
or a 96-well plate ELISAd
~US$0.1 $489.00
a As measured in our lab (sensitivity claimed by the manufacturer). b ESI, Table S2. c ESI, Table S3. d ESI, Table S1.
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View Article Onlinesamples for a total of 4096 assays per chip. To the best of our
knowledge, the throughput of our diagnostic microfluidic
platform is ~100 times higher than current state-of-the-art
microfluidic platforms.11,13,25–35 To demonstrate the utility of
our platform, we quantified different protein biomarkers
from a few nanoliters of human serum and compared these
to conventional ELISA, showing a good correlation and simi-
lar sensitivities as ELISA.
Scaling a standard immunoassay to nanoliter volumes
has several significant consequences: i) thousands of assays
can be performed in parallel on a single device, ii) reagent
cost is reduced by several orders of magnitude, and iii) only
a few nanoliters are required per sample. Additionally, our
approach does not require sample preparation or sample
pretreatment since serum samples can be directly arrayed
and assayed.
It is now theoretically possible to test a single standard
blood sample of 10 mL for a very large panel of biomarkers
since 4 biomarkers can be tested for every 5 nL of sample,
and the cost per biomarker is 0.0001 US$. For example, sam-
ples could be spotted on different glass slides, aligned to a
microfluidic device, and each device measures a set of four
different biomarkers. Additionally, small-volume serum sam-
ples of 50–100 μL would be easier to acquire, and to ship,
and would be sufficient to run hundreds of tests using our
serum analyzer platform. Indeed, small volume samples
could be acquired by a simple pin-prick, and produce suffi-
cient sample for microfluidic analysis, especially if diluted
2–10 fold in a stabilizing buffer.
It is also possible to perform several technical repeats for
each sample at essentially no additional cost, which increases
the precision of the measurement. Although we have exclu-
sively used the sample mean and sample standard deviation
to summarize our measurements in the manuscript, the stan-
dard error is more appropriate in some regards as it provides
an estimate of the precision of the calculated sample mean.
The mean and standard deviation describe the shape of the
Gaussian distribution (centrality and spread). The standard
error on the other hand provides an estimate of the precisionThis journal is © The Royal Society of Chemistry 2014of the measured sample mean. The standard error depends
on n (SE = σ/n1/2). Thus, the more measurements are taken
for a given sample the smaller the SE and the precision of
the measurement increases (the measured sample mean will
be closer to the actual population mean and the confidence
intervals will be narrower). By extension, the accuracy of the
LOD can be expected to also slightly improve with increased
n. The LOD is commonly defined as the sample mean of a
negative blank plus 3 standard deviations. Increasing the
number of measurements of the blank sample will improve
the accuracy of the LOD value itself, as both the mean and
standard deviation become more accurate. More importantly,
if a sample is measured which has a population (true) mean
equal to the LOD, and only a single measurement is taken
then, assuming a symmetric measurement error, this mea-
surement by definition has a 50% probability of being a false
negative (to fall below the LOD). If many measurements are
taken from the same sample, the precision of the sample
mean increases. Thus, the sample mean is less likely to be
significantly different from the actual population mean and
thus is less likely to lead to a false negative (or conversely to
a false positive, if the actual sample mean is below the LOD).
Extremely low sample volume requirements are particu-
larly appealing for serum samples acquired during clinical
trials or samples stored in biobanks. Our microfluidic
nanoimmunoassay platform allows re-analysis of samples for
additional biomarkers that have not been included in the ini-
tial study. Limited and non-renewable samples stored in
biobanks can also now be analyzed many times, without risk
of exhausting the sample stock. Equally attractive is the fact
that samples can be pre-arrayed on glass slides, followed by
long-term storage of the arrays, thus completely eliminating
freeze–thaw cycles, which can lead to sample degradation.
In the future, our chip could be integrated with label-free
biosensors to eliminate the need for secondary antibodies,
further decreasing the cost of the platform and eliminating
the need for optical readout.36 Multiplexing of biomarkers
could be increased at least 4-fold by generating concentric
annuli by tuning the pressure of the button membraneLab Chip
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ferent biomarker.10 Improvements in sensitivity could be pos-
sible by adapting single-molecule detection techniques37–40
or through the implementation of amplification schemes.
More generally, we have shown that our microfluidic
MITOMI platform9,41–43 is capable of measuring protein
biomarkers in hundreds to thousands of samples with high-
sensitivity and high dynamic-range.7,10 The approach is
matrix insensitive, meaning that sample origin is generally
not important, and we have demonstrated that the platform
is compatible with cell culture supernatants, mouse serum,
mouse bronchoalveolar lavage (BAL), and now human serum.
Our approach is thus high-throughput, precise, sensitive,
cost-effective, and widely applicable, and thus should find
many uses in diagnostics, as well as systems biology,44 specif-
ically in signal pathway analysis, where it is becoming
increasingly necessary to quantitate many proteins in large
numbers of samples.45
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